# Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/atezolizumab-versus-docetaxel-for-patients-with-previously-treated-non-small/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Louis Fehrenbacher,Alexander I. Spira,Marcus Ballinger,Marcin Kowanetz,Johan Vansteenkiste,Julien Mazières,Keunchil Park,David C. Smith,Á. Artal,C. Lewanski,Fadi Braiteh,Daniel Waterkamp,Pei He,Wei Zou,Daniel S. Chen,Jing Yi,Alan Sandler,Achim Rittmeyer |
| Citations | 2,812 |
| DOI | 10.1016/s0140-6736(16)00587-0 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2293531514 |
| PMID | 26970723 |
| Type | article |
| Year | 2016 |

## Paper authors

- [Keunchil Park](https://scholariq.org/researchers/keunchil-park/)
- [Julien Mazières](https://scholariq.org/researchers/julien-mazieres/)

## Paper journal

- [The Lancet](https://scholariq.org/journals/the-lancet/)

## Paper primary topic

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Paper topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Peptidase Inhibition and Analysis](https://scholariq.org/topics/peptidase-inhibition-and-analysis/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.